Tibet Rhodiola Pharmaceutical Holding Company operates in the Drugs, proprietaries, and sundries sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Tibet Rhodiola Pharmaceutical Holding Company with three other
companies in this sector in China:
Kingworld Medicines Group Limited
sales of 1.05 billion Chinese Renmimbi [US$159.17 million]
of which 90%
was Distribution sales of pharmaceutical and),
China NT Pharma Group Co Ltd
(915.12 million Chinese Renmimbi [US$138.26 million]
of which 62%
was Third-party Pharmaceutical Promotion & S), and
GuangYuYuan Chinese Herbal Medicine Co Ltd
(933.68 million Chinese Renmimbi [US$141.06 million]
of which 15%
was Drug Industry).
Tibet Rhodiola Pharmaceutical Holding Company reported sales of 796.77 million Chinese Renmimbi (US$120.38 million)
December of 2016.
decrease of 42.3%
versus 2015, when the company's sales were 1.38 billion Chinese Renmimbi.
Contributing to the drop in overall sales was the 68.9% decline
in Other, from 7.03 million Chinese Renmimbi to 2.19 million Chinese Renmimbi.
However, these declines were partially offset by the increase in sales of
Pharmaceutical Manufacturing Industry (up 54.3% to 794.62 million Chinese Renmimbi)